REFERENCES
2. Liu M, Wei AC. Advances in surgery and (Neo) adjuvant therapy in the management of pancreatic cancer. Hematol Oncol Clin North Am 2024;38:629-42.
3. Conroy T, Hammel P, Hebbar M, et al; Canadian Cancer Trials Group and the Unicancer-GI–PRODIGE Group. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med 2018;379:2395-406.
4. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013;369:1691-703.
5. Steele NG, Biffi G, Kemp SB, et al. Inhibition of hedgehog signaling alters fibroblast composition in pancreatic cancer. Clin Cancer Res 2021;27:2023-37.
6. Chung S, Vail P, Witkiewicz AK, Knudsen ES. Coordinately targeting cell-cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res 2019;25:2290-304.
7. Huffman BM, Feng H, Parmar K, et al. A phase I expansion cohort study evaluating the safety and efficacy of the CHK1 inhibitor LY2880070 with low-dose gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2023;29:5047-56.
8. Laquente B, Lopez-Martin J, Richards D, et al. A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer 2017;17:137.
9. Barnard D, Diaz HB, Burke T, et al. LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models. Invest New Drugs 2016;34:49-60.
10. Cuneo KC, Morgan MA, Sahai V, et al. Dose escalation trial of the Wee1 inhibitor adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol 2019;37:2643-50.
11. Dunlop CR, Wallez Y, Johnson TI, et al. Complete loss of ATM function augments replication catastrophe induced by ATR inhibition and gemcitabine in pancreatic cancer models. Br J Cancer 2020;123:1424-36.
12. Wallez Y, Dunlop CR, Johnson TI, et al. The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther 2018;17:1670-82.
13. Schepis T, De Lucia SS, Pellegrino A, et al. State-of-the-art and upcoming innovations in pancreatic cancer care: a step forward to precision medicine. Cancers 2023;15:3423.
14. Li Petri G, Pecoraro C, Randazzo O, et al. New imidazo[2,1-b][1,3,4]thiadiazole derivatives inhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma. Anticancer Res 2020;40:4913-9.
15. Pecoraro C, De Franco M, Carbone D, et al. 1,2,4-amino-triazine derivatives as pyruvate dehydrogenase kinase inhibitors: synthesis and pharmacological evaluation. Eur J Med Chem 2023;249:115134.
16. Boutros R, Lobjois V, Ducommun B. CDC25 phosphatases in cancer cells: key players? Good targets? Nat Rev Cancer 2007;7:495-507.
17. Lammer C, Wagerer S, Saffrich R, Mertens D, Ansorge W, Hoffmann I. The cdc25B phosphatase is essential for the G2/M phase transition in human cells. J Cell Sci 1998;111:2445-53.
18. Lindqvist A, Källström H, Lundgren A, Barsoum E, Rosenthal CK. Cdc25B cooperates with Cdc25A to induce mitosis but has a unique role in activating cyclin B1-Cdk1 at the centrosome. J Cell Biol 2005;171:35-45.
19. Galaktionov K, Lee AK, Eckstein J, et al. CDC25 phosphatases as potential human oncogenes. Science 1995;269:1575-7.
20. Guo J, Kleeff J, Li J, et al. Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 2004;23:71-81.
21. Li R, Wu B, Xia J, Ye L, Yang X. Circular RNA hsa_circRNA_102958 promotes tumorigenesis of colorectal cancer via miR-585/CDC25B axis. Cancer Manag Res 2019;11:6887-93.
22. Li S, Peng F, Ning Y, et al. SNHG16 as the miRNA let-7b-5p sponge facilitates the G2/M and epithelial-mesenchymal transition by regulating CDC25B and HMGA2 expression in hepatocellular carcinoma. J Cell Biochem 2020;121:2543-58.
23. Liu JC, Granieri L, Shrestha M, et al. Identification of CDC25 as a common therapeutic target for triple-negative breast cancer. Cell Rep 2018;23:112-26.
24. Singh L, Pushker N, Sen S, et al. Expression of CDC25A and CDC25B phosphatase proteins in human retinoblastoma and its correlation with clinicopathological parameters. Br J Ophthalmol 2015;99:457-63.
25. Nakabayashi H, Hara M, Shimizu K. Prognostic significance of CDC25B expression in gliomas. J Clin Pathol 2006;59:725-8.
26. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Mussi A, Fontanini G. CDC25B: relationship with angiogenesis and prognosis in non-small cell lung carcinoma. Hum Pathol 2007;38:1563-8.
27. Miyata H, Doki Y, Shiozaki H, et al. CDC25B and p53 are independently implicated in radiation sensitivity for human esophageal cancers. Clin Cancer Res 2000;6:4859-65.
28. Garcia PL, Miller AL, Kreitzburg KM, et al. The BET bromodomain inhibitor JQ1 suppresses growth of pancreatic ductal adenocarcinoma in patient-derived xenograft models. Oncogene 2016;35:833-45.
29. Miller AL, Garcia PL, Fehling SC, et al. The BET inhibitor JQ1 augments the antitumor efficacy of gemcitabine in preclinical models of pancreatic cancer. Cancers 2021;13:3470.
30. Garcia PL, Council LN, Christein JD, et al. Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma. PLoS One 2013;8:e78183.
31. Miller AL, Fehling SC, Garcia PL, et al. The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. EBioMedicine 2019;44:419-30.
32. Garcia PL, Miller AL, Zeng L, van Waardenburg RCAM, Yang ES, Yoon KJ. The BET inhibitor JQ1 potentiates the anticlonogenic effect of radiation in pancreatic cancer cells. Front Oncol 2022;12:925718.
33. Kang CM, Cho HN, Ahn JM, et al. Alteration of gene expression during radiation-induced resistance and tumorigenesis in NIH3T3 cells revealed by cDNA microarrays: involvement of MDM2 and CDC25B. Carcinogenesis 2004;25:123-32.
34. Pan X, Xu C, Cheng G, Chen Z, Liu M, Mei Y. Transcription factor E2F3 activates CDC25B to regulate DNA damage and promote mitoxantrone resistance in stomach adenocarcinoma. Mol Biol Rep 2024;51:90.
35. Miller AL, Garcia PL, Gamblin TL, Vance RB, Yoon KJ. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma. Cancer Drug Resist 2020;3:572-85.
36. Miller AL, Fehling SC, Vance RB, et al. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine. Cancer Lett 2024;592:216919.
37. Thomas Y, Peter M, Mechali F, Blanchard JM, Coux O, Baldin V. Kizuna is a novel mitotic substrate for CDC25B phosphatase. Cell Cycle 2014;13:3867-77.
38. Kishi K, van Vugt MA, Okamoto K, Hayashi Y, Yaffe MB. Functional dynamics of Polo-like kinase 1 at the centrosome. Mol Cell Biol 2009;29:3134-50.
39. Bona AB, Calcagno DQ, Ribeiro HF, et al. Menadione reduces CDC25B expression and promotes tumor shrinkage in gastric cancer. Therap Adv Gastroenterol 2020;13:1756284819895435.
40. Hu YC, Lam KY, Law S, Wong J, Srivastava G. Identification of differentially expressed genes in esophageal squamous cell carcinoma (ESCC) by cDNA expression array: overexpression of Fra-1, Neogenin, Id-1, and CDC25B genes in ESCC. Clin Cancer Res 2001;7:2213-21.
41. Ngan ES, Hashimoto Y, Ma ZQ, Tsai MJ, Tsai SY. Overexpression of Cdc25B, an androgen receptor coactivator, in prostate cancer. Oncogene 2003;22:734-9.
42. Xiao Y, Yu Y, Gao D, et al. Inhibition of CDC25B with WG-391D impedes the tumorigenesis of ovarian cancer. Front Oncol 2019;9:236.
43. Ito Y, Yoshida H, Tomoda C, et al. Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis. Cancer Lett 2005;229:291-7.
44. Kudo Y, Yasui W, Ue T, et al. Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. Jpn J Cancer Res 1997;88:947-52.
45. Zhang Z, Zhang G, Kong C. High expression of Cdc25B and low expression of 14-3-3σ is associated with the development and poor prognosis in urothelial carcinoma of bladder. Tumour Biol 2014;35:2503-12.
46. Brenner AK, Reikvam H, Lavecchia A, Bruserud Ø. Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules 2014;19:18414-47.
47. Dalvai M, Mondesert O, Bugler B, Manenti S, Ducommun B, Dozier C. Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter. Oncogene 2013;32:5123-8.
48. Brisson M, Nguyen T, Vogt A, et al. Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase. Mol Pharmacol 2004;66:824-33.
49. George Rosenker KM, Paquette WD, Johnston PA, et al. Synthesis and biological evaluation of 3-aminoisoquinolin-1(2H)-one based inhibitors of the dual-specificity phosphatase Cdc25B. Bioorg Med Chem 2015;23:2810-8.
50. Li HL, Ma Y, Ma Y, et al. The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches. Oncotarget 2017;8:33225-40.
